Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Open Label Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study of SF1126, A PI3 Kinase (PI3K) Inhibitor, Given Twice Weekly By IV Infusion To Patients With Advanced or Metastatic Tumors

NCT00907205 is registered in ClinicalTrials.gov with Semafore Pharmaceuticals as lead sponsor.

NCT NCT00907205
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00907205 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Open Label Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study of SF1126, A PI3 Kinase (PI3K) Inhibitor, Given Twice Weekly By IV Infusion To Patients With Advanced or Metastatic Tumors
Lead sponsor
Semafore Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2007
Completion date
April 30, 2011
Enrollment
44 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or metastatic solid tumors, cancer, solid cancers